IMATINIB AS CHOLESTEROL DECREASING AGENT

摘要

The present invention relates to imatib for use in the treatment of hyperlipidemia, hypercholesterolemia or hypertriglyceridemia. Already after 6 months treatment, imatinib was found to sustainably decrease the cholesterol ratio (total cholesterol / HDL cholesterol), to sustainably increase HDL cholesterol blood levels, and to sustainably decrease LDL cholesterol and triglyceride blood levels. Thus, imatinib represents a new lipid-modifying drug that results in cardiovascular benefits.